These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16452174)

  • 1. Germ line polymorphism in metastatic progression.
    Hunter KW; Crawford NP
    Cancer Res; 2006 Feb; 66(3):1251-4. PubMed ID: 16452174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host genetics influence tumour metastasis.
    Hunter K
    Nat Rev Cancer; 2006 Feb; 6(2):141-6. PubMed ID: 16491073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genetic and epigenetic alterations associated with cancer metastasis].
    Tani M; Yokota J
    Gan To Kagaku Ryoho; 1999 Nov; 26(13):2101-5. PubMed ID: 10584580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients.
    Inoue T; Ito T; Narita S; Horikawa Y; Tsuchiya N; Kakinuma H; Mishina M; Nakamura E; Kato T; Ogawa O; Habuchi T
    Cancer Lett; 2006 Aug; 240(1):41-7. PubMed ID: 16229939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
    Tirkkonen M; Johannsson O; Agnarsson BA; Olsson H; Ingvarsson S; Karhu R; Tanner M; Isola J; Barkardottir RB; Borg A; Kallioniemi OP
    Cancer Res; 1997 Apr; 57(7):1222-7. PubMed ID: 9102202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating germline and somatic data towards a personalized cancer medicine.
    Pujana MA
    Trends Mol Med; 2014 Aug; 20(8):413-5. PubMed ID: 25086750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
    Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
    Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer.
    Adjadj E; Schlumberger M; de Vathaire F
    Lancet Oncol; 2009 Feb; 10(2):181-90. PubMed ID: 19185836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics of breast cancer progression.
    Ingvarsson S
    Semin Cancer Biol; 1999 Aug; 9(4):277-88. PubMed ID: 10448115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological principles for multimodal therapy approaches].
    Schackert HK; Bornhäuser M; Dörr W; Frank S
    Zentralbl Chir; 2000; 125(4):306-14. PubMed ID: 10829309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genetic factors involved in cancer susceptibility].
    Kohno T; Yokota J
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1255-62. PubMed ID: 12146010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer.
    Horak P; Pils D; Roessler M; Tomek S; Elandt K; Zeillinger R; Zielinski C; Krainer M
    Gynecol Oncol; 2005 May; 97(2):514-8. PubMed ID: 15863153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the Influence of Germline Variation on Metastasis Using Systems Genetics Approaches.
    Lee M; Crawford NP
    Adv Cancer Res; 2016; 132():73-109. PubMed ID: 27613130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline TP53 mutations and single nucleotide polymorphisms in children.
    Valva P; Becker P; Streitemberger P; Lombardi GM; Rey G; Guzman CA; Preciado MV
    Medicina (B Aires); 2009; 69(1 Pt 2):143-7. PubMed ID: 19414295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in research on the molecular pathogenesis of the malignant tumours and implications for their early diagnosis and treatment].
    Steffen J
    Med Wieku Rozwoj; 2000; 4(2 Suppl 2):11-25. PubMed ID: 11178325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression.
    Oliveira C; Sousa S; Pinheiro H; Karam R; Bordeira-Carriço R; Senz J; Kaurah P; Carvalho J; Pereira R; Gusmão L; Wen X; Cipriano MA; Yokota J; Carneiro F; Huntsman D; Seruca R
    Gastroenterology; 2009 Jun; 136(7):2137-48. PubMed ID: 19269290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
    Shin KH; Park YJ; Park JG
    Clin Cancer Res; 2000 Feb; 6(2):536-40. PubMed ID: 10690536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of XRCC1 gene polymorphisms with the susceptibility and chromosomal aberration of testicular germ cell tumors.
    Tsuchiya N; Mishina M; Narita S; Kumazawa T; Inoue T; Horikawa Y; Kakinuma H; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
    Int J Oncol; 2006 May; 28(5):1217-23. PubMed ID: 16596238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic alterations and metabolic polymorphisms.
    Freedman AN
    IARC Sci Publ; 1999; (148):37-50. PubMed ID: 10493247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.